Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Neuralstem Updates NSI-189 Major Depression Trial

June 20, 2011 By Bio-Medicine.Org

ROCKVILLE, Md., June 20, 2011 /PRNewswire/ — Neuralstem, Inc.
(NYSE Amex:
CUR
) announced that it has been approved to dose the final
cohort in the ongoing Phase Ia trial to test the safety of NSI-189
for the treatment of major depression. Phase Ia is testing the drug
in healthy volunteers for safety and tolerability. NSI-189 is a
proprietary new chemical entity discovered by Neuralstem that
stimulates new neuron growth in the hippocampus, an area of the
brain that is believed to be involved in depression and other
diseases and conditions, such as Alzheimer’s disease and
post-traumatic stress disorder (PTSD).

(Logo:
http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

“The trial is proceeding as expected,” said Karl Johe, PhD,
Chief Scientific Officer and Chairman of Neuralstem’s Board of
Directors. “There have been no adverse events to date. We are on
schedule to complete Phase Ia in July, and with approval from the
FDA, plan to begin Phase Ib this fall.” Phase Ib will test the
safety and tolerability of NSI-189 in patients with major
depression.

About NSI-189

NSI-189 is the lead compound in Neuralstem’s neurogenerative
small molecule drug platform, which the company plans to develop
into orally administered drugs for major  depression and other
psychiatric disorders.

NSI-189 stimulated neurogenesis of human hippocampus-derived
neural stem cells in-vitro. In mice, NSI-189 stimulated
neurogenesis in the hippocampus and increased its volume. In
humans, NSI-189 may reverse the human hippocampal atrophy seen in
major depression and other disorders. This program has received
significant support from both the Defense Advanced Research
Projects Agency (DARPA) and the National Institutes of Health
(NIH).

About the Trial

This Phase Ia trial tests a single dose of NSI-189 in healthy
patients. If the safety endpoints ar

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech